Vimarsana
Biggest News Aggregation in the World

Page 3 - Equal Life News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Equal Life. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Equal Life Today - Breaking & Trending Today

Results from Astellas' Pivotal Phase 3 SKYLIGHT 1™ Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The Lancet - Vimarsana News

Results from Astellas' Pivotal Phase 3 SKYLIGHT 1™ Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The Lancet

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced The Lancet published detailed results...

Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients - Vimarsana News

Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients

China has the world’s largest iron deficiency anemia population with estimated prevalence of 15%1 Approval may also benefit the Chinese healthcare system, among others through implementation... | November 28, 2022

Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously - Vimarsana News

Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously

L’AFP est une agence d’information globale, assurant une couverture rapide, complète et vérifiée des événements de l’actualité comme des thèmes qui façonnent notre quotidien. Avec un réseau de journalistes sans égal, déployé sur 151 pays, l'AFP est en outre un leader mondial de l’investigation nu...

Source: afp.com
The Burden of Metastatic Cancer–Induced Bone Pain: A Narrative R - Vimarsana News

The Burden of Metastatic Cancer–Induced Bone Pain: A Narrative R

The Burden of Metastatic Cancer–Induced Bone Pain: A Narrative Review

Astellas to Present Findings from Phase 3 Long-Term Safety Study of Fezolinetant in Oral Session at The North American Menopause Society 2022 Annual Meeting - Vimarsana News

Astellas to Present Findings from Phase 3 Long-Term Safety Study of Fezolinetant in Oral Session at The North American Menopause Society 2022 Annual Meeting

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will present 52-week results from the Phase 3 SKYLIGHT...